ClinicalTrials.gg
CompletedNCT01613950Updated Dec 9, 2020

PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer

A Phase 1 interventional study of AUY922 and BYL719 in Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein, sponsored by Novartis Pharmaceuticals. Completed at 9 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 676 studies in Esophageal Neoplasms with a site in United States — 122 open to participants now, 172 under way, 2 of them phase 3. Esophageal Neoplasms · United States.

Enrollment
412th of 525
18 · median 42
Started
2012
with 18 others
Phase 1
167 of 676
29 open now
Registered
308th of 676
by date

Among the 676 studies in Esophageal Neoplasms with a site in United States, this one is the 412th largest by enrollment of the 525 interventional ones that give a count, is one of 19 that started in 2012, is one of 167 in phase 1, and was the 308th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 503 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

122 of the 676 studies in Esophageal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

117 more — sign in →

All 122 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 388 Esophageal Neoplasms studies recruiting now, 246 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 676 studies in Esophageal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The study is intended to investigate the safety of BYL719 and AUY922 in patients with advanced gastric cancer, and to determine the MTD and/or RDE of both drugs in combination. In addition, the preliminary efficacy of BYL719 in combination with AUY922, and the pharmacokinetics of both drugs will be assessed. Patients will be eligible for this study, if their tumors carry either a molecular alteration of PIK3CA, or an amplification of HER2.

The study includes a dose escalation part followed by a safety expansion phase.

03

Conditions studied

  • Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein

Keywords

  • gastric cancer advanced gastric or metastatic gastric cancer PI3K PIK3CA mutation Her2 amplification HSP90 inhibitor PI3K inhibitor PIK3CA amplification
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patients with advanced or adenocarcinoma of the stomach or gastroesophageal junction;
  • Patients must not have a complete gastrectomy;
  • gastric tumors carrying PIK3CA mutation or amplification, or -overexpression, or both;
  • at least one but no more than three for advanced or metastatic disease;
  • Patients with PIK3CA mutated or amplified tumors must have failed at least one line but no more than three lines of standard chemotherapy and/or targeted agents;Patients with HER2 amplified tumor must have failed at least one line, but no more than three lines, with or without anti-HER2 therapy. All HER2 positive patients are expected to have received trastuzumab unless were present or trastuzumab was unavailable;
  • Performance Status (PS) ≤ 1 ;
  • Adequate bone marrow, liver and other organ functions and laboratory parameters;
  • Recovery from all AEs of previous anti-cancer therapies, including surgery and radiotherapy, to baseline or to Grade ≤ 1, except for alopecia;Negative serum pregnancy (β hCG) test within 72 hrs before starting study treatment in all pre-menopausal women and women \< 12 months after the onset of menopause.

    * Exclusion Criteria:

  • Progressive disease during or after prior combination treatment with PI3K-inhibitors and HSP90- inhibitors;
  • history of prior significant toxicity from another PI3K- or HSP90- inhibitor requiring discontinuation of treatment;
  • primary CNS tumor or uncontrolled CNS metastasest;
  • Patients who are currently receiving medication with a known risk of prolonging the or inducing Torsades de Pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug treatment;
  • Patients with diabetes mellitus requiring insulin treatment and/or with clinical signs or with fasting glucose ≥ 140 mg/dL / 7.8 mmol/L, history of gestational diabetes mellitus or documented -induced diabetes mellitus;Patients with diarrhea CTCAE Grade ≥ 2 ;
  • Patients with acute or chronic pancreatitis; History or current evidence of central serous retinopathy (CSR), retinal vein occlusion (RVO) or ophthalmopathy as assessed by ophthalmologic examination at baseline that would be considered a risk factor for CSR/RVO;
  • Impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral BYL719;
  • Patients receiving chronic slow-release formulation of Proton Pump Inhibitors (PPI), H2-antagonists or other gastric pH elevating agents;
  • Treatment with therapeutic doses of coumarin-based anticoagulants (e.g., warfarin sodium, Coumadin®). Low doses of courmarin-based anticoagulants;
  • Patients receiving chronic or high dose corticosteroids therapy; other protocol-defined inclusion/exclusion criteria may apply.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    BYL719 + AUY922

    Dose finding study to estimate the maximum tolerated dose(s) (MTD) and/or recommended dose(s) for safety expansion (RDE) followed by an expansion phase to further assess the safety and preliminary activity of the combination. BYL719 tablets will be administered orally on a daily schedule (q.d.). a b.i.d. regimen may be explored. AUY922 will be administered by IV infusion once per week.

    Drug: AUY922 · Drug: BYL719

Interventions

  • DrugAUY922

    AUY922 is a non-geldanamycin inhibitor of the heat shock protein 90 (HSP90).

  • DrugBYL719

    BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.

06

What researchers measure

Primary outcomes

  1. Incidence rate of Dose Limiting Toxicities.

    To determine the maximum tolerated dose (MTD) and/or Recommended dose for expansion (RDE) and schedule of BYL719 and AUY922 when used as a combination in patients with advanced or metastatic gastric cancer carrying a molecular alteration of PIK3CA and/or an amplification of HER2. 1 cycle = 28days

    Time frame: cycle 1

Secondary outcomes

  1. Frequency of adverse events (AEs)

    To characterize the safety and tolerability of BYL719 and AUY922 in combination.

    Time frame: duration of the study, an expected average of 24 months

  2. Best Overall Response (BOR) as per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1

    To assess the preliminary anti-tumor activity of BYL719/AUY922 combination from Treatment start to disease progression

    Time frame: every 6 weeks

  3. Plasma concentration versus time profiles of BYL719 as single agent an in combination with AUY922.

    To determine the single dose PK of BYL719 single dose, and multiple doses PK of BYL719.

    Time frame: 2 months

  4. Overall response rate (ORR) as per RECIST version 1.1

    To assess the preliminary anti-tumor activity of BYL719/AUY922 combination.

    Time frame: an expected average of 12 months

  5. Progression free survival (PFS) as per RECIST version 1.1

    To assess the preliminary anti-tumor activity of BYL719/AUY922 combination.

    Time frame: every 6 weeks

  6. Overall survival (OS)

    To assess the preliminary anti-tumor activity of BYL719/AUY922 combination.

    Time frame: approximately 1 year

  7. Overall survival rate at 6 months (OS6)

    To assess the preliminary anti-tumor activity of BYL719/AUY922 combination.

    Time frame: 6 months

  8. Frequency and severity of serious adverse events (SAEs)

    To characterize the safety and tolerability of BYL719 and AUY922 in combination.

    Time frame: duration of the study, an expected average of 24 months

  9. Plasma concentration versus time profile of AUY922 as single agent and in combination with BYL719

    To determine the single dose and multiple dose pharmacokinetics of AUY922

    Time frame: 2 months

  10. Plasma concentration versus time profile of the AUY922 metabolite BJP762

    To determine pharmacokinetics of BJP762 after single dose and multiple dose of AUY922

    Time frame: 2 months

  11. Severity of adverse events (AEs)

    To characterize the safety and tolerability of BYL719 and AUY922 in combination.

    Time frame: duration of the study, an expected average of 24 months

07

Study locations

9 sites
  • Massachusetts General Hospital Mass General 2
    Boston, Massachusetts 02114, United States
  • University of Texas/MD Anderson Cancer Center Gastrointestinal Med. Oncology
    Houston, Texas 77030-4009, United States
  • Novartis Investigative Site
    Köln, 50924, Germany
  • Novartis Investigative Site
    Würzburg, 97080, Germany
  • Novartis Investigative Site
    Chuo-ku, Tokyo, Japan
  • Novartis Investigative Site
    Seoul, Korea 110 744, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 738-736, Korea, Republic of
  • Novartis Investigative Site
    Bellinzona, 6500, Switzerland
  • Novartis Investigative Site
    Taipei, 10048, Taiwan
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2012
First posted
Jun 7, 2012
Start
Dec 2012
Primary completionActual
Mar 2014
CompletionActual
Mar 2014
Last update
Dec 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01613950
Responsible party
Sponsor
First posted
Jun 7, 2012
Start date
Dec 2012
Primary completion
Mar 2014
Completion
Mar 2014
Last update
Dec 9, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: auy922 · Alpelisib

Start the discussion